Nocturnal hemodialysis can improve anemia treatment in hemodialysis patients

SUN Ke; LIU Zi-yu; TANG Xiao-jing; MA Yi-yi; MEI Chang-lin

doi:10.3969/j.issn.1671-2390.2019.06.003

Journal of Clinical Nephrology > 2019 > 19(6): 396-400. > DOI: 10.3969/j.issn.1671-2390.2019.06.003

SUN Ke, LIU Zi-yu, TANG Xiao-jing, MA Yi-yi, MEI Chang-lin. Nocturnal hemodialysis can improve anemia treatment in hemodialysis patients[J]. Journal of Clinical Nephrology, 2019, 19(6): 396-400. DOI: 10.3969/j.issn.1671-2390.2019.06.003

Citation:

PDF (476 KB)

Nocturnal hemodialysis can improve anemia treatment in hemodialysis patients

Department of Nephrology, Chang zheng Hospital, Naval Military Medical University, Shanghai 200003, China

More Information

Received Date: November 05, 2018
Available Online: May 11, 2023
Published Date: June 27, 2019

Graphical Abstract

Abstract

Abstract

Objective To compare effect of nocturnal hemodialysis(NHD) versus conventional hemodialysis (CHD) on anemia treatment in hemodialysis patients, to investigate whether the treatment of anemia was improved in patients receiving of nocturnal hemodialysis (NHD) when compared with conventional hemodialysis (CHD). Methods A total of 39 patients with NHD undergoing dialysis in Chang zheng Hospital, Naval Military Medical University from February 2009 to December 2017, were selected, of which 21 patients with CHD were changed into those with NHD. By matching gender, age and initial hemoglobin levels of patients, based on time sequence, 60 patients with CHD were selected. General condition, ferritin, transferrin saturation, C-reactive protein (CRP), and the interdialytic doses of and ferric preparation and transfusion event rate were compared between the patients in the two groups. Results There was no significant difference in CRP, ferratin and transferrin saturation at baseline between the NHD and CHD groups during enrollment (P>0.05). The EPO dose at the final follow-up in the NHD group was lower than that in the CHD group (103.4±53.6 IU·kg^-1·w^-1 vs 126.34±54.9 IU·kg^-1·w^-1, P<0.05), and the ferric preparation use rate in the NHD group was lower than that in the CHD group. There was no significant difference between the two groups in CRP, ferratin and transferrin saturation between the two groups. For those 21 patients who changed dialysis model, the hemoglobin level at the final follow-up was higher than that at baseline (P<0.05); the ferritin, transferrin saturation and CRP had no significant difference from those before changing the dialysis model (P>0.05); and the mean EPO dose had no significant difference compared to that at 1 year before changing the treatment model (106±34.6 IU·kg^-1·w^-1 vs 110±30.9 IU·kg^-1·w^-1). Conclusions Compared with conventional hemodialysis, nocturnal hemodialysis can reduce the doses of EPO and intravenous ferric preparation in dialysis patients, and achieve the improved control of anemia in hemodialysis patients.
- Nocturnal hemodialysis,
- Anemia,
- EPO

FullText(HTML)

References (36)

References

[1]	Teasdale EJ, Leydon G, Fraser S, et al. Patients' Experiences After CKD Diagnosis:A Meta-ethnographic Study and Systematic Review[J]. Am J Kidney Dis, 2017,70(5):656-665.
[2]	Zhang L, Wang F, Wang L, et al. Prevalence of chronic kidney disease in China:a cross-sectional survey[J]. Lancet, 2012, 379(9818):815-822.
[3]	Ng YH, Meyer KB, Kusek JW, et al. Hemodialysis timing, survival, and cardiovascular outcomes in the Hemodialysis (HEMO) Study[J]. Am J Kidney Dis, 2006, 47(4):614-624.
[4]	Jansz TT, Bonenkamp AA, Boereboom FTJ, et al. Health-related quality of life compared between kidney transplantation and nocturnal hemodialysis[J]. PLoS One, 2018, 13(9):415-416.
[5]	Li L, Tang X, Kim S, et al.. Effect of nocturnal hemodialysis on sleep parameters in patients with end-stage renal disease:a systematic review and meta-analysis[J]. PLoS One, 2018,13(9):371-374.
[6]	Wong B, Collister D, Muneer M, et al. In-Center Nocturnal Hemodialysis Versus Conventional Hemodialysis:A Systematic Review of the Evidence[J]. Am J Kidney Dis, 2017, 70(2):218-234.
[7]	Luik AJ, Charra B, Katzarski K, et al. Blood pressure control and hemodynamic changes in patients on long time dialysis treatment[J]. Blood Purif, 1998, 16(4):197-209.
[8]	Basile C, Libutti P, Di Turo AL, et al. Hemodynamic stability in standard bicarbonate hemodialysis and long-hour slow-flow bicarbonate haemodialysis[J]. Nephrol Dial Transplant, 2011, 26(1):252-258.
[9]	Hanly PJ, Pierratos A. Improvement of sleep apnea in patients with chronic renal failure who undergo nocturnal hemodialysis[J]. N Engl J Med, 2001, 344(2):102-107.
[10]	Lindsay RM, Alhejaili F, Nesrallah G, et al. Calcium and phosphate balance with quotidian hemodialysis[J]. Am J Kidney Dis, 2003, 42(1):24-29.
[11]	McFarlane PA. Nocturnal hemodialysis:effects on solute clearance, quality of life, and patient survival[J]. Curr Opin Nephrol Hypertens, 2011, 20(2):182-188.
[12]	康梅子,薛澄,付莉莉,等.中心夜间透析和传统透析患者循环成纤维细胞生长因子23水平差异及影响因素[J].第二军医大学学报,2017,38(1):27-33.
[13]	Eckardt KU. Anemia in end-stage renal disease:pathophysiological considerations[J]. Nephrol Dial Transplant, 2001, 16(7):2-8.
[14]	Zalunardo N, Levin A. Anemia and the heart in chronic kidney disease[J]. Semin Nephrol, 2006, 26(4):290-295.
[15]	Li S, Collins AJ. Association of hematocrit value with cardiovascular morbidity and mortality in incident hemodialysis patients[J]. Kidney Int, 2004, 65(2):626-633.
[16]	Nitta K. Clinical assessment and management of dyslipidemia in patients with chronic kidney disease[J]. Clin Exp Nephrol, 2012, 16(4):522-529.
[17]	Furuhashi M, Ishimura S, Ota H, et al. Serum fatty acid-binding protein 4 is a predictor of cardiovascular events in end-stage renal disease[J]. PLoS One, 2011, 6(11):234-256.
[18]	Rao M, Muirhead N, Klarenbach S, et al. Management of anemia with quotidian hemodialysis[J]. Am J Kidney Dis, 2003, 42(1):18-23.
[19]	Ok E, Duman S, Asci G, et al. Comparison of 4-and 8-h dialysis sessions in thrice-weekly in-center hemodialysis:a prospective, case-controlled study[J]. Nephrol Dial Transplant, 2011, 26(4):1287-1296.
[20]	Lacson E Jr. Wang W, Lester K, et al. Outcomes associated with in-center nocturnal hemodialysis from a large multicenter program[J]. Clin J Am Soc Nephrol, 2010, 5(2):220-226.
[21]	Wald R, Goldstein MB, Perl J, et al. The Association Between Conversion to In-centre Nocturnal Hemodialysis and Left Ventricular Mass Regression in Patients with End-Stage Renal Disease[J]. Can J Cardiol, 2016, 32(3):369-377.
[22]	Jin X, Rong S, Mei C, et al. Effects of thrice-weekly in-center nocturnal vs. conventional hemodialysis on integrated backscatter of myocardial tissue[J]. Hemodial Int, 2011,15(2):200-210.
[23]	Jin X, Rong S, Mei C, et al.. Effects of in-center nocturnal versus conventional hemodialysis on endothelial dysfunction[J]. Ther Apher Dial, 2012,16(4):334-340.
[24]	Weinreich T, De los Rios T, Gauly A, et al. Effects of an increase in time vs. frequency on cardiovascular parameters in chronic hemodialysis patients[J]. Clin Nephrol, 2006, 66(6):433-439.
[25]	Powell JR, Oluwaseun O, Woo YM, et al. Ten years experience of in-center thrice weekly long overnight hemodialysis[J]. Clin J Am Soc Nephrol, 2009, 4(6):1097-1101.
[26]	David S, Kumpers P, Eisenbach GM, et al. Prospective evaluation of an in-centre conversion from conventional hemodialysis to an intensified nocturnal strategy[J]. Nephrol Dial Transplant, 2009, 24(7):2232-2240.
[27]	Alloatti S, Molino A, Manes M, et al. Long nocturnal dialysis[J]. Blood Purif, 2002, 20(6):525-530.
[28]	Gubensek J, Buturovic-Ponikvar J, Knap B, et al. Effect of switching to nocturnal thrice-weekly hemodialysis on clinical and laboratory parameters:our experience[J]. Ther Apher Dial, 2013, 17(4):412-415.
[29]	Graham-Brown MP, Churchward DR, Smith AC, et al. A 4-month program of in-center nocturnal hemodialysis was associated with improvements in patient outcomes[J]. Clin Kidney J, 2015, 8(6):789-795.
[30]	Dai WD, Zhang DL, Cui WY, et al. Effect of long intermittent hemodialysis on improving dialysis adequacy of maintenance hemodialysis patients[J]. Chin Med J, 2013, 126(24):4655-4659.
[31]	Fajardo L, Campistrus N, Rios P, et al. Evolution of serum phosphate in long intermittent hemodialysis[J]. Kidney Int suppl,2003,85:S66-68.
[32]	Bugeja A, Dacouris N, Thomas A, et al. In-center nocturnal hemodialysis:another option in the management of chronic kidney disease[J]. Clin J Am Soc Nephrol, 2009, 4(4):778-783.
[33]	Galli F, Beninati S, Benedetti S, et al. Polymeric protein-polyamine conjugates:a new class of uremic toxins affecting erythropoiesis[J]. Kidney Int Suppl, 2001, 78(13):S73-76.
[34]	Macdougall IC. Role of uremic toxins in exacerbating anemia in renal failure[J]. Kidney Int Suppl, 2001, 78(24):S67-72.
[35]	Goldfarb-Rumyantzev AS, Cheung AK, Leypoldt JK. Computer simulation of small-solute and middle-molecule removal during short daily and long thrice-weekly hemodialysis[J]. Am J Kidney Dis, 2002, 40(6):1211-1218.
[36]	Rioux JP, Chan CT. Nocturnal home hemodialysis and its impact on erythropoietin responsiveness[J]. Clin Nephrol, 2010, 74(3):167-172.

[1]	Li Chun-min, Wen Qian, Luo Dan, Wu Jun. Correlation analysis of systemic inflammatory response index with erythropoietin hyporesponsiveness and clinical prognosis in maintenance hemodialysis patients[J]. Journal of Clinical Nephrology, 2025, 25(2): 121-129. DOI: 10.3969/j.issn.1671-2390.2025.02.005
[2]	Wang Li-li, Yang Man-ling, Hou Jing, Wang Li-juan. Efficacy and safety of roxadustat in hemodialysis patients with renal anemia based upon the changes of erythropoietin, interleukin-6 and △Hbmax[J]. Journal of Clinical Nephrology, 2023, 23(5): 357-362. DOI: 10.3969/j.issn.1671-2390.2023.05.002
[3]	Luo Yu-qing, Xu Qing-yu, Ji Li-ke, Zhu Qiong-jie, Shi Jing-jing, Guo Ming-hao. Real world study based upon Roxadustat for improving renal anemia in peritoneal dialysis patients[J]. Journal of Clinical Nephrology, 2023, 23(4): 313-319. DOI: 10.3969/j.issn.1671-2390.2023.04.006
[4]	Zhang Peng-jie, Xun Li-ru, Ding Tong, Bao Nan, Duan Bin. Clinical efficacy and safety analysis in initial hemodialysis patient with renal anemia treated by roxadustat or recombinant human erythropoietin[J]. Journal of Clinical Nephrology, 2022, 22(11): 917-923. DOI: 10.3969/j.issn.1671-2390.2022.11.006
[5]	XU Leng-nan, CHEN Xian-guang, LI Chuan-bao, LIU Xin, SUN Ying, MAO Yong-hui. Significance of reticulocyte hemoglobin content in the treatment of anemia in maintenance hemodialysis patients[J]. Journal of Clinical Nephrology, 2020, 20(11): 853-856. DOI: 10.3969/j.issn.1671-2390.2020.11.001
[6]	SU Chao, BIAN Xian-qian, WANG Gang, ZHANG Qu, DU Ting-ting, HE Heng-jie. The difference of efficacy between Shengxuening and Polysaccharide iron complex capsule in treating renal anemia in patients with hemodialysis[J]. Journal of Clinical Nephrology, 2020, 20(4): 293-296,321. DOI: 10.3969/j.issn.1671-2390.2020.04.006
[7]	WANG Yu-jie, GUO Zhi-yong, LAI Xue-li. A case of pure red cell aplasia anemia induced by recombinant human erythropoietin[J]. Journal of Clinical Nephrology, 2020, 20(3): 259-261. DOI: 10.3969/j.issn.1671-2390.2020.03.018
[8]	WU Xin-hong, ZHANG Yun. Study on the mechanism of action of NGAL in renal anemia on iron metabolism and erythrocyte maturation[J]. Journal of Clinical Nephrology, 2019, 19(11): 847-852. DOI: 10.3969/j.issn.1671-2390.2019.11.012
[9]	ZHANG Yong, HOU Juan. Efficacy of L-carnitine combined with erythropoietin in the treatment of hemodialysis-induced renal anemia[J]. Journal of Clinical Nephrology, 2018, 18(3): 176-179. DOI: 10.3969/j.issn.1671-2390.2018.03.011
[10]	NI Hua, PENG Jia-qing. Analysis of related factors in maintenance hemodialysis patients with renal anemia[J]. Journal of Clinical Nephrology, 2017, 17(7): 427-430. DOI: 10.3969/j.issn.1671-2390.2017.07.011

Cited By

Cited by

Periodical cited type(3)

1.	李军. 青年维持性血液透析病人对夜间血液透析认知与态度的质性研究. 循证护理. 2021(03): 397-400 .
2.	吕艳. 维持性血液透析病人对夜间血液透析的意向调查及影响因素分析. 循证护理. 2021(06): 810-813 .
3.	郑长新，刘先鸿，李拉. 罗沙司他对初始透析患者肾性贫血的疗效及血红蛋白的影响. 罕少疾病杂志. 2021(06): 60-62 .

Other cited types(0)

Get Citation

PDF

XML

Article views (411) PDF downloads (358) Cited by(3)

Turn off MathJax

Article Contents

Abstract

References

Nocturnal hemodialysis can improve anemia treatment in hemodialysis patients

Abstract

References

Related Articles

Cited by

Periodical cited type(3)

Other cited types(0)

Catalog

Nocturnal hemodialysis can improve anemia treatment in hemodialysis patients

Abstract

References

Related Articles

Cited by

Periodical cited type(3)

Other cited types(0)

Catalog

Export File

Citation

Format

Content